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Background: Several lung diseases are increasingly recognized as comorbidities with HIV; however, few data exist
related to the spectrum of respiratory symptoms, diagnostic testing, and diagnoses in the current HIV era. The
objective of the study is to determine the impact of HIV on prevalence and incidence of respiratory disease in the
current era of effective antiretroviral treatment.
Methods: A pulmonary-specific questionnaire was administered yearly for three years to participants in the
Multicenter AIDS Cohort Study (MACS) and Women’s Interagency HIV Study (WIHS). Adjusted prevalence ratios for
respiratory symptoms, testing, or diagnoses and adjusted incidence rate ratios for diagnoses in HIV-infected
compared to HIV-uninfected participants were determined. Risk factors for outcomes in HIV-infected individuals
were modeled.
Results: Baseline pulmonary questionnaires were completed by 907 HIV-infected and 989 HIV-uninfected
participants in the MACS cohort and by 1405 HIV-infected and 571 HIV-uninfected participants in the WIHS cohort.
In MACS, dyspnea, cough, wheezing, sleep apnea, and incident chronic obstructive pulmonary disease (COPD) were
more common in HIV-infected participants. In WIHS, wheezing and sleep apnea were more common in
HIV-infected participants. Smoking (MACS and WIHS) and greater body mass index (WIHS) were associated with
more respiratory symptoms and diagnoses. While sputum studies, bronchoscopies, and chest computed
tomography scans were more likely to be performed in HIV-infected participants, pulmonary function tests were no
more common in HIV-infected individuals. Respiratory symptoms in HIV-infected individuals were associated with
history of pneumonia, cardiovascular disease, or use of HAART. A diagnosis of asthma or COPD was associated with
previous pneumonia.
Conclusions: In these two cohorts, HIV is an independent risk factor for several respiratory symptoms and
pulmonary diseases including COPD and sleep apnea. Despite a higher prevalence of chronic respiratory symptoms,
testing for non-infectious respiratory diseases may be underutilized in the HIV-infected population.
Keywords: AIDS, HIV, Pulmonary disease, Chronic obstructive, Respiratory tract diseases, Sleep apnea syndromes* Correspondence: gingomr@upmc.edu
1Department of Medicine, School of Medicine, University of Pittsburgh,
Pittsburgh, PA, USA
Full list of author information is available at the end of the article
© 2014 Gingo et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Gingo et al. BMC Pulmonary Medicine 2014, 14:75 Page 2 of 12
http://www.biomedcentral.com/1471-2466/14/75Background
With widespread use of highly active antiretroviral ther-
apy (HAART) for treatment of HIV, the incidence of
infectious complications of HIV and related mortality
has declined [1,2]. Although treatment has led to in-
creased longevity in HIV-infected persons, there may be
an increase in morbidity and mortality secondary to
non-AIDS related conditions [3-5]. Chronic lung condi-
tions may contribute to morbidity and mortality as con-
ditions such as chronic obstructive pulmonary disease
(COPD), [1,6,7] bronchogenic carcinoma, [8] pulmonary
hypertension, [9] and pulmonary fibrosis [1] have been
reported to be more prevalent in HIV-infected persons.
Prior studies have been based largely on medical record
review, and little is known about the prevalence of re-
spiratory symptoms, degree of diagnostic testing related
to cardiopulmonary disease, and prevalence and inci-
dence of patient-reported diagnoses related to chronic
lung disease in HIV-infected persons during the current
HAART era.
The increased prevalence of risk behaviors such as
cigarette smoking and illicit drug use in the HIV popu-
lation [10-12] make it difficult to determine the inde-
pendent effect of HIV infection on occurrence of lung
disease. Prior to HAART, studies showed that HIV
was associated with a greater prevalence of respiratory
symptoms and emphysema [13,14]. Recent studies have
shown respiratory symptoms and pulmonary disease to
be common in HIV-infected persons, [1,15-19] but these
studies are limited as they are based on administrative
data, do not address symptoms or performance of diag-
nostic testing, or lack an appropriate HIV-uninfected
group for comparison.
In order to assess the magnitude of chronic respiratory
disease and symptoms related to HIV infection, we sur-
veyed the participants of the Multicenter AIDS Cohort
Study (MACS) and the Women’s Interagency HIV Study
(WIHS), two large cohorts of HIV-infected and HIV-
uninfected individuals. We tested the hypothesis that re-
spiratory symptoms and chronic lung diseases are more
common in HIV-infected persons and identified factors
related to a diagnosis of lung disease in HIV-infected
individuals.
Methods
Participants
The MACS and WIHS cohorts have been described pre-
viously [20,21]. Briefly, the MACS is a prospectively
followed cohort of 6,972 men with or at risk for HIV
started in 1984, and the WIHS is a prospectively followed
cohort of 3,766 women with or at risk for HIV started in
1994. The MACS is primarily a cohort of men who have
sex with men, and WIHS is a cohort of women who en-
gage in high risk behavior for HIV infection, primarilyintravenous drug use. Participants in this study were HIV-
infected and HIV-uninfected individuals who completed a
pulmonary questionnaire at an ongoing MACS or WIHS
study visit between January 2008 and December 2010. All
participants were eligible. If participants did not complete
a baseline pulmonary questionnaire during the 2008 visit
cycle, they were excluded from further study. All partici-
pants gave written informed consent to study protocols
approved by the institutional review boards of participat-
ing sites (University of Pittsburgh; Women’s Interagency
HIV Study Data Management and Analysis Center; Johns
Hopkins University; University of California, Los Angeles;
University of California, San Francisco; State University
of New York Downstate Medical Center; Northwestern
University; and the Center for Analysis and Management
of Multicenter AIDS Cohort Study).
Data collection
At yearly MACS or WIHS visits from 2008 to 2010, par-
ticipants responded to a modified American Thoracic
Society-Division of Lung Disease-78 Respiratory Disease
Questionnaire [22] that collected information regarding
frequency of respiratory symptoms (cough, phlegm pro-
duction, wheezing, and dyspnea) and prevalent (2008) and
then incident (2009, 2010) therapies (medication, oxygen
therapy, nocturnal non-invasive ventilation), diagnostic
testing (self-report of having had sputum sampling, bron-
choscopy, chest computed tomography [CT], pulmonary
function testing, echocardiography, or polysomnography),
and chronic diagnoses (self-report of having been told
they had asthma, COPD, chronic bronchitis, lung fibrosis,
sarcoidosis, pulmonary hypertension, pulmonary emboli,
and sleep apnea). Baseline pulmonary questionnaire asked
if the participant had ever had diagnostic testing, and
follow-up pulmonary questionnaires if they had diagnostic
testing in the past year. Participants were considered to
have significant respiratory symptoms if they reported that
symptoms occurred more frequently than just with colds
or infections and were experienced at least monthly. The
presence of any COPD was defined as having been told
they had a diagnosis of COPD, chronic bronchitis, or
emphysema.
Time-dependent data were determined from the visit
at which the prevalence pulmonary questionnaire was
administered (2008) and included age, HIV status, dur-
ation of HIV infection, body mass index (BMI), cigarette
smoking status, cumulative pack-years of cigarette smok-
ing, alcohol consumption, use of intravenous drugs in
the past 6 months, use of cocaine in the past 6 months,
diagnosis of cardiac disease (by self-report of myocardial
infarction, hospitalization for congestive heart failure
hospitalization for chest pain/angina, surgery on heart
vessels, or other heart disease) use of HAART, current
CD4 count, and current plasma HIV RNA level. Data
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used to determine participants’ ever-use of intravenous
drugs or cocaine, history of tuberculosis, history of
Pneumocystis or bacterial pneumonia, duration of HAART
use, and mean and nadir CD4 counts. HIV status was de-
termined by HIV serological testing at each visit in previ-
ously seronegative participants, and participants who were
HIV positive at baseline visit were assumed to have dur-
ation of HIV infection from time of MACS or WIHS en-
rollment to the date corresponding to the prevalence
pulmonary questionnaire visit. Race, ethnicity, cigarette
smoking history, alcohol consumption, and illicit drug use
were determined by participant self-report. Alcohol con-
sumption was categorized as none, light drinking (<3
drinks/week), moderate drinking (3-13 drinks/week), or
heavy drinking (≥14 drinks/week). HAART was defined
previously [23] and categorized as never, past HAART
use, or current HAART use.
Statistical analysis
The MACS and WIHS cohorts were analyzed separately
because of variations in data collection procedures and
differences in the populations sampled, including gender,
proportions of minorities, socioeconomic status, access
to health care, and substance use. To assess selection
bias, characteristics (age, race/ethnicity, smoking history,
alcohol use, drug use, HIV status, and CD4 counts and
viral loads) were compared between participants in each
cohort who completed the prevalence pulmonary ques-
tionnaire to those who were enrolled in the cohort and
did not complete the questionnaire. For participants
who had not completed the prevalence pulmonary ques-
tionnaire because they failed to show for the scheduled
visit, data were carried forward from the last visit they
had attended.
Personal characteristics, clinical data, presence of re-
spiratory symptoms, medical therapies, diagnostic testing,
and diagnoses were compared between HIV-infected and
HIV-uninfected groups in each cohort using parametric
(t-tests) and non-parametric (chi-square, Wilcoxon) tests
as appropriate. Respiratory symptoms, medical therapies,
diagnostic testing, and diagnoses were also compared
between HIV-infected and HIV-uninfected groups in
each cohort stratified by smoking status because cigarette
smoking is such a dominant risk factor for lung disease.
To determine incidence of pulmonary diagnoses from
follow-up questionnaires (2009-2010), incidence rates for
specific pulmonary diseases were computed in those who
did not report that disease at the prevalence pulmonary
questionnaire (2008) as the number of observed incident
events divided by the number of person-years of follow-
up, where the follow-up time available for each person
was the number of years from the initial pulmonary evalu-
ation visit until the earliest of the following: diseasediagnosis date, death, loss to follow-up, or the date of the
last visit with a pulmonary questionnaire.
Multivariable modeling was then performed for the
most prevalent conditions: symptoms, diagnostic testing,
asthma, COPD, and sleep apnea. Poisson regression me-
thods [24] were used to examine the association of base-
line measures and HIV status with baseline prevalence of
respiratory symptoms, diagnostic testing, and diagnoses,
and to identify potential confounders. Baseline charac-
teristics examined included age, African-American race,
Hispanic ethnicity, smoking status, pack-years smoked, al-
cohol status, intravenous drug use ever, cocaine use ever,
and hepatitis C status. Adjusted prevalence ratio models
were fitted with robust variance to quantify the association
of HIV status with the outcomes independent of the effect
of race, smoking status, intravenous drug use ever, age,
and any additional significant factors (p < 0.05) added from
the above multivariable model. Similar models were re-
peated restricting to HIV-infected participants to assess
HAART use, CD4 cell counts, and plasma HIV RNA
levels, and an additional set of models restricted to HIV-
infected participants were performed to include history of
cardiovascular disease and history of Pneumocystis or bac-
terial pneumonia to assess for contributions of these vari-
ables. We also assessed if protease inhibitors were related
to symptoms or diagnoses by including protease inhibitor
use in the model instead of HAART use, but there were
no associations with this specific antiretroviral category
(data not shown). To evaluate the associations between in-
cident diagnoses during the two-year follow-up and HIV
status, we fit separate multivariable Poisson regression
models to incidence data [25,26]. For covariates with simi-
lar origin (for example current or ever using intravenous
drugs or the current or mean CD4 count), the variable
with the lowest bivariate p-value was included in the
model. Prevalence ratios or rate ratios and 95% confidence
intervals were reported for all outcomes. An interaction
between HIV infection and smoking status was also test
by adding an interaction term to the final multivariable
models. A p-value <0.05 determined statistical signifi-
cance. We analyzed data using SAS Version 9.2 (SAS, Inc.,
Cary, NC).
Results
Participants
The prevalence pulmonary questionnaire was completed at
a study visit in 2008 by 907 HIV-infected and 989 HIV-
uninfected participants in the MACS cohort and 1405
HIV-infected and 571 HIV-uninfected participants in the
WIHS cohort. There were 223 MACS participants and 488
WIHS participants who did not complete the prevalence
pulmonary questionnaire (Additional file 1: Table S1). In
both cohorts, equal proportions of HIV-infected par-
ticipants completed the questionnaire. Participants who
Gingo et al. BMC Pulmonary Medicine 2014, 14:75 Page 4 of 12
http://www.biomedcentral.com/1471-2466/14/75completed the questionnaire were more likely to be older,
Caucasian, use recreational drugs, and have lower plasma
HIV RNA levels. In WIHS, there were fewer never-
smokers and more never drinkers of alcohol in participants
who completed the questionnaire, and Hispanics were
more likely to complete the questionnaire.Table 1 Participant characteristics
HIV-uninfected
N = 989
Age, mean (SD) 52.3 (10.7)
African American, n (%) 185 (18.7)
Hispanic, n (%) 72 (7.3)
BMI, n (%) 27.2 (5.1)
Smoking status, n (%)
Never 258 (26.3)
Former 499 (50.9)
Current 223 (22.8)
Pack years, median (Q1-Q3) 0.5 (0-20)
Alcohol use, n (%)
None 155 (15.8)
Light 463 (47.3)
Moderate 264 (27.0)
Heavy 97 (9.9)
Intravenous drug use-ever, n (%) 88 (8.9)
Cocaine use-ever, n (%) 427 (43.2)
Hepatitis C positive, n (%) 73 (7.4)
Cardiovascular diagnosis ever, n (%) 67 (6.8)
Bacterial pneumonia ever, n (%) 43 (4.3)
Pneumocystis pneumonia ever, n (%) -
M. tuberculosis infection ever, n (%) 1 (0.1)
Antiretroviral medication use, n (%)
None -
Prior HAART -
Current HAART -
HAART duration, mean (SD) -
Protease inhibitor use ever, n (%) -
CD4 counts (cells/uL), mean (SD)
Current, at baseline pulmonary questionnaire 932.6 (311.5)
Mean over the period followed in cohort 971.4 (274.6)
Nadir during period followed in cohort 622.7 (224.9)
Plasma HIV RNA level (copies/mL), median (Q1-Q3) -
Plasma HIV RNA undetectable, n (%)*
*HIV RNA level at baseline pulmonary questionnaire visit available in 843 MACS and
cohort and <80 copies/mL in the WIHS cohort.
BMI – body mass index; MACS - Multicenter AIDS Cohort Study; WIHS - Women’s In
Q1 - quartile 1; Q3 - quartile 3.There were significant differences in demographic and
clinical factors between the HIV-infected and HIV-
uninfected participants in each cohort at the time of the
prevalent questionnaire (Table 1). In the MACS cohort,
HIV-infected individuals were younger, more likely to
be African-American, smoked more, and used cocaineMACS WIHS
HIV-infected HIV-uninfected HIV-infected
N = 907 p-value N = 571 N = 1405 p-value
49.2 (8.8) <0.001 40.8 (10.1) 44.4 (8.7) <0.001
297 (32.8) <0.001 363 (63.6) 820 (58.4) 0.03
98 (10.8) 0.007 149 (26.1) 392 (27.9) 0.41
25.6 (4.4) <0.001 30.6 (8.4) 28.1 (7.4) <0.001
<0.001 <0.001
222 (24.8) 136 (23.9) 441 (31.8)
395 (44.1) 139 (24.4) 404 (29.2)
278 (31.1) 295 (51.7) 540 (39.0)
4 (0-21) 0.02 13 (0.5-25.5) 13.2 (0-26.1) 0.28
<0.001 <0.001
201 (22.5) 274 (48.1) 896 (64.7)
477 (53.4) 178 (31.2) 351 (25.3)
165 (18.5) 93 (16.3) 91 (6.6)
50 (5.6) 25 (4.4) 47 (3.4)
145 (16.0) <0.001 119 (20.8) 376 (26.8) 0.006
520 (57.3) <0.001 329 (57.6) 773 (55.0) 0.29
138 (15.2) <0.001 105 (18.5) 405 (28.9) <0.001
80 (8.8) 0.1 29 (5.1) 47 (3.4) 0.07
109 (12.0) <0.001 31 (5.4) 250 (17.8) <0.001
49 (5.4) - 1 (0.2) 150 (10.7) <0.001
2 (0.2) 0.51 14 (2.5) 97 (6.9) <0.001
150 (16.8) - - 326 (23.2) -
43 (4.8) - - 8 (0.6) -
702 (78.4) - - 1071 (76.2) -
14.1 (7.9) - - 15.5 (8.3) -
636 (70.1) - - 1024 (72.9) -
571.8 (277.4) <0.001 1039.9 (331.3) 502 (291.2) <0.001
579.9 (230.7) <0.001 1059.1 (309.6) 490.2 (217.8) <0.001
259.5 (168.6) <0.001 728.8 (269.9) 209.9 (156.2) <0.001
40 (40-136) - - 80 (80-2400) -
590 (70.0) 764 (56.0)
1365 WIHS participants. Undetectable level was <40 copies/mL in the MACS
teragency HIV Study; SD - standard deviation; n - number; % - percentage;
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cohort, HIV-infected individuals were older, less likely to
be African-American, and less likely to smoke than HIV-
uninfected participants. HIV-infected participants in both
cohorts had lower BMI and were less likely to drink, but
were more likely to use intravenous recreational drugs, be
hepatitis C seropositive, and have had pneumonia com-
pared to HIV-uninfected individuals.
The majority of HIV-infected participants in both co-
horts were on HAART (78.4% and 76.2% in MACS and
WIHS, respectively) at the time of the prevalence pulmon-
ary questionnaire with a mean (SD) duration of HAART
use of 14.1 (7.9) years in MACS and 15.5 (8.3) years in
WIHS. HIV-infected participants had a mean (SD) CD4+
T-cell count at the time of the prevalence pulmonary
questionnaire of 571.8 (277.4) cells/uL in MACS and 502
(291.2) cells/uL in WIHS, and the majority of participantsFigure 1 Prevalence of respiratory symptoms in the Multicenter AIDS
(b), diagnostic testing in MACS (c) and WIHS (d), and respiratory diagno
CT - computed tomography, PFT - pulmonary function testing, PSG - polys
CB - chronic bronchitis, PH - pulmonary hypertension. (*) represents a p-vahad undetectable viral loads (MACS: plasma HIV RNA
level < = 40copies/mL: 590/843 = 70%; WIHS: plasma HIV
RNA level < =80 copies/mL: 764/1365 = 56%).
Respiratory symptoms and treatments
Respiratory symptoms and inhaler use were common in
both cohorts at the time of the prevalence pulmonary
questionnaire (Additional file 1: Table S2), and HIV was
an independent risk factor for certain symptoms. In the
MACS cohort, phlegm production, dyspnea, any respira-
tory symptoms, and inhaler use were reported more com-
monly by HIV-infected participants (Figure 1a), and in the
WIHS cohort, only oxygen use was reported more com-
monly in HIV-infected participants, although oxygen use
was uncommon overall (Figure 1b). In regression models,
HIV infection was independently associated with greater
prevalence of cough (prevalence ratio [PR], 1.11; p = 0.03),Cohort (MACS) (a) and Women’s Interagency HIV Study (WIHS)
ses in MACS (e) and WIHS (f) by HIV status. ECHO - echocardiogram,
omnography, COPD - chronic obstructive pulmonary disease,
lue < 0.05 by chi-square test.
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and having any respiratory symptom (PR, 1.11; p = 0.003)
in the MACS cohort and associated with wheezing (PR,
1.19; p = 0.02), inhaler use (PR 1.14; p = 0.04), and oxygen
use (PR 3.43; p = 0.01) in the WIHS cohort (Table 2).
Diagnostic testing
Patterns of the use of respiratory diagnostic testing varied
significantly according to HIV status. Diagnostic tests com-
monly used to evaluate acute respiratory infections such as
sputum testing, bronchoscopy, and chest CT scans were
more likely in HIV-infected participants (Figure 1c-d).
Despite a greater prevalence of chronic respiratory symp-
toms in HIV-infected participants, HIV-infected individ-
uals in either cohort were no more likely to have mainstay
testing for chronic respiratory disease such as pulmonary
function testing (Table 2). HIV-infected participants in
MACS were more likely to have an echocardiogram and
polysomnography.
Prevalence of respiratory diagnoses
Obstructive lung diseases were the most commonly re-
ported prevalent diagnosis (Figure 1e,f). In both cohorts,Table 2 Association of HIV status and prevalent pulmonary o
MACS
PR (95% CI) for HIV-infected
Symptoms
Cough 1.11 (1.01-1.21)
Dyspnea 1.25 (1.02-1.53)
Wheeze 1.20 (1.00-1.44)
Sputum 1.08 (0.97-1.20)
Any symptom 1.11 (1.04-1.19)
Inhaler use 1.17 (0.99-1.38)
Oxygen use 1.12 (0.57-2.19)
Diagnostic testing
Sputum testing 2.93 (2.24-3.83)
Bronchoscopy 2.73 (1.75-4.28)
Chest CT 1.28 (1.11-1.47)
Pulmonary function tests 1.04 (0.92-1.17)
Echocardiogram 1.27 (1.11-1.46)
Polysomnography 1.30 (1.06-1.59)
Diagnoses
Asthma 1.04 (0.80-1.34)
Sleep apnea 1.42 (1.10-1.84)
Any COPD 1.31 (0.80-2.14)
Models are adjusted for age, race, smoking status, pack-years smoked, intravenous
outcome (p < 0.05) in stepwise regression.
MACS - Multicenter AIDS Cohort Study; WIHS - Women’s Interagency HIV Study; PR
COPD - chronic obstructive pulmonary disease.asthma was the most common diagnosis. Asthma preva-
lence was strikingly high in the WIHS cohort in both
HIV-infected (22.9%) and HIV-uninfected (25.7%) par-
ticipants, but not significantly different by HIV status.
COPD diagnoses were also common and mostly attrib-
utable to chronic bronchitis, but were no more likely in
HIV-infected compared to HIV-uninfected in either
cohort.
Sleep apnea appeared to occur at similar prevalence
rates in HIV-infected and HIV-uninfected men as well
as women, however, when adjusting for confounders
such as age and BMI, HIV-infected participants were
more likely to have been diagnosed with sleep apnea in
both MACS, (PR, 1.42; p = 0.01) and WIHS (PR, 2.10;
p = 0.002) (Table 2).
The prevalences were low and did not differ between
HIV-infected and HIV-uninfected participants for the
diagnoses of pulmonary hypertension (MACS: HIV-
infected, 0.6% vs. HIV-uninfected, 0.4%; WIHS: 0.7% vs.
1.0%), interstitial pulmonary fibrosis (MACS: 0% vs. 0.2%;
WIHS: 0% vs. 0.2%), sarcoidosis (MACS: 0.4% vs. 0.2%;
WIHS: 0.2% vs. 0.9%), and pulmonary embolism (MACS:
0.5% vs. 1.0%; WIHS: 0.4% vs. 0.7%).utcomes for each cohort
WIHS
p-value PR (95% CI) for HIV-infected p-value
0.03 1.02 (0.95-1.09) 0.61
0.03 1.09 (0.98-1.20) 0.12
0.04 1.19 (1.03-1.38) 0.02
0.18 1.08 (0.98-1.19) 0.11
0.003 1.04 (0.99-1.10) 0.12
0.06 1.14 (1.00-1.30) 0.04
0.75 3.43 (1.36-8.66) 0.01
<0.001 2.88 (2.13-3.89) <0.001
<0.001 1.67 (0.94-2.98) 0.08
0.001 1.24 (1.00-1.53) 0.05
0.55 0.97 (0.82-1.15) 0.76
0.001 1.02 (0.83-1.27) 0.82
0.01 1.33 (0.92-1.93) 0.13
0.78 1.05 (0.88-1.25) 0.57
0.01 2.10 (1.31-3.36) 0.002
0.28 1.35 (0.82-2.24) 0.24
drug use, and other factors noted to be significantly associated with the
- Prevalence ratio; CI - confidence intervals; CT – computed tomography;
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When analysis was performed comparing prevalence of
symptoms, diagnostic testing, and diagnoses between
HIV-infected and HIV-uninfected subjects stratified by
smoking, there appeared to be increased prevalence of
outcomes with former and current smoking compared
to never smokers (Additional file 1: Table S4a and b).
Compared to HIV-uninfected never smokers, HIV-infected
men who were never smokers were more likely to have
dyspnea and have had bronchoscopy and sputum sam-
pling performed. Compared to HIV-uninfected former
smokers, HIV-infected men who were former smokers
were more likely to have phlegm production, use in-
halers, and have had chest CT, bronchoscopy, and sputum
sampling performed, and compared to HIV-uninfected
current smokers, HIV-infected men who were current
smokers were more likely to have had chest CT, echo-
cardiogram, or sputum sampling performed. HIV-infected
women were more likely to have sputum sampling done
independent of smoking status, but compared to HIV-
uninfected former smokers who were women, female
HIV-infected former smokers were more likely to have
had chest CT. Compared to HIV-uninfected current
smoker women, HIV-infected current smokers were
more likely to have wheezing, use an inhaler, and be di-
agnosed with COPD and chronic bronchitis. An inter-
action between smoking status and HIV infection was
not found to be significant for any respiratory symp-
toms or diagnoses.Incidence of respiratory diagnoses
Incidence of diagnoses was determined during 2 years fol-
lowing the prevalence questionnaire. Men had a higher in-
cidence rate of sleep apnea compared to women, while
women had higher incidence rates for asthma and COPD
compared to men (Table 3). HIV-infected individuals were
more likely to report a new diagnosis of COPD in the
MACS cohort (rate ratio [RR], 2.21; p = 0.03), and there
was a borderline association with HIV and increased inci-
dent sleep apnea (RR 2.33; p = 0.08) in the WIHS cohort.Table 3 Estimates for the effect of HIV infection on incidence
MACS
Incident rates per 100
person-years
RR (95% CI) p-v
Diagnosis HIV-infected HIV-uninfected HIV-infected vs.
HIV-uninfected
Asthma 0.69 0.62 0.86 (0.35-2.13) 0.75
COPD 1.70 0.69 2.21 (1.09-4.50) 0.03
Sleep apnea 1.41 1.45 0.92 (0.49-1.73) 0.81
Adjusted for age, race, smoking status, and intravenous drug use.
MACS – Multicenter AIDS Cohort Study; WIHS – Women’s Interagency HIV Study; RR
pulmonary disease.Relationship of HIV-associated variables and respiratory
symptoms, treatments, testing, and diagnoses
HIV-related variables such as nadir CD4 cell count, HIV
viral load, and HAART use were also associated with
respiratory symptoms, diagnostic testing, and diagnoses
(Additional file 1: Table S3a). In HIV-infected participants
in both the MACS and WIHS cohorts, diagnostic testing
such as sputum and bronchoscopy were more likely in
those with lower nadir CD4 cell counts (Additional file 1:
Table S3a). In WIHS HIV-infected participants, COPD
was more likely with higher plasma HIV RNA levels.
We also included cardiovascular disease and history of
bacterial or Pneumocystis pneumonia in models (Additional
file 1: Table S3b). In MACS, there were associations of
cardiovascular disease and history of pneumonia with vari-
ous respiratory symptoms (cardiovascular disease, bac-
terial pneumonia), increased likelihood of bronchoscopy
(cardiovascular disease, bacterial pneumonia) or sputum
induction (bacterial pneumonia, Pneumocystis pneumo-
nia), and with diagnoses of asthma (bacterial pneumonia)
and COPD (bacterial pneumonia). Lower nadir CD4
counts were no longer associated with increased chance of
sputum testing and bronchoscopy. In WIHS, dyspnea was
significantly increased in those with cardiovascular disease
or a history of bacterial pneumonia with a trend to being
more common in those on HAART (Additional file 1:
Table S3b). Wheezing was also more common in those
with a history of bacterial pneumonia or in those using
HAART. Individuals with a history of cardiovascular dis-
ease were more likely to have had an echocardiogram and
those with bacterial pneumonia or Pneumocystis pneumo-
nia were more likely to have had a bronchoscopy of spu-
tum induction. A history of pneumonia was more common
in individuals with asthma (bacterial pneumonia) or COPD
(bacterial or Pneumocystis pneumonia). Higher HIV RNA
level was no longer significantly associated with a COPD
diagnosis.
Discussion
This study is the first during the current HAART era of the
HIV epidemic to assess respiratory symptoms, diagnosticof pulmonary diagnoses
WIHS
alue Incident rates per 100
person-years
RR (95% CI) p-value
HIV-infected HIV-uninfected HIV-infected vs.
HIV-uninfected
2.59 3.35 0.87 (0.54-1.41) 0.58
2.13 1.39 1.58 (0.85-2.94) 0.15
1.12 0.49 2.33 (0.89-6.11) 0.09
– Rate ratio; CI – confidence interval; COPD – chronic obstructive
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compare them between HIV-infected and HIV-uninfected
persons in a large, multicenter study. We found that HIV
infection was independently associated with higher preva-
lence of certain respiratory symptoms, with certain aspects
of HIV associated with different respiratory symptoms.
Despite an increase in chronic respiratory symptoms, the
HIV-infected groups were no more likely to have evalu-
ation of non-infectious pulmonary diseases, suggesting
that these diseases may be underdiagnosed in HIV. HIV
infection was an independent risk factor for prevalent
sleep apnea and incident (in MACS) COPD.
Persons infected with HIV have been noted to have a
high burden of respiratory symptoms, both during the
pre-HAART [14] and the current HAART eras [17]. Our
findings support that HIV infection confers an independ-
ent risk for increased respiratory symptoms, and poor
HIV control may contribute to the increase in symptoms,
although the relationship to various aspects of immuno-
suppression is likely variable and complex. The impact of
respiratory symptoms on quality of life in this population
is unclear, but increased respiratory symptom burden and
medication use may add significantly to the frailty experi-
enced by patients [27].
As non-infectious pulmonary diseases emerge as im-
portant causes of morbidity and mortality in the current
era of HIV, our data suggest that these chronic pulmonary
disorders are likely under-recognized and therefore under-
treated. Despite the increase in symptoms, diagnostic
testing in HIV did not reflect the burden of chronic re-
spiratory symptoms. Testing generally used to diagnose
infectious complications of HIV (such as sputum testing,
bronchoscopy, and CT scans) were more common in HIV,
but despite an increase in chronic respiratory symptoms
and greater self-report of diagnoses such as COPD and
sleep apnea in the HIV-infected groups, there was no in-
crease in testing such as pulmonary function in either co-
hort or in polysomnography in WIHS that would assess
these conditions. This finding may reflect a diagnostic bias
which prevents many physicians from evaluating HIV-
infected persons for chronic respiratory conditions such as
asthma or COPD and suggests that these diseases may ac-
tually be more common in HIV than recognized.
Our findings build on prior data that HIV infection is
independently associated with COPD in cohorts of vet-
erans or intravenous drug users [1,6,7]. Accelerated em-
physema and COPD have long been seen in HIV
infection, [28] and recent studies have confirmed this as-
sociation in the HAART era [1,7]. Our study is a cohort
that represents a population different from those in prior
studies of veterans [1] or intravenous drug abusers [7].
We also found that higher viral load was associated with
a diagnosis of COPD, similar to a recent study finding
airflow obstruction associated with viral load greaterthan 200,000 copies/μL. The prior study controlled for a
history of bacterial pneumonia, but when we added a
history of cardiovascular disease, bacterial pneumonia,
and Pneumoycstis pneumonia to the models, these fac-
tors were more strongly associated than viral load, sug-
gesting that poorly controlled HIV may be associated
with COPD either directly through prior infections or
through common pathways linking HIV, cardiovascular
disease and COPD [7].
We determined that HIV was significantly associated
with sleep apnea, which has not been reported previously
in a cohort of this size. Unlike smoking-related diseases
such as COPD, [12,29] the most common risk factor for
sleep apnea, heavier body mass, [30] was not more com-
mon in HIV-infected persons. Yet, HIV-infected persons
were more likely to be diagnosed and treated for sleep
apnea despite lower average BMI. Prior literature suggests
that sleep apnea in HIV may be related less to traditional
anthropomorphic risks seen in the general population [31]
and may be explained by upper airway abnormalities re-
lated to adenoid or tonsilar hypertrophy [32]. Metabolic
disease and abnormal adipose distribution related to HIV
infection and antiretroviral medications [33] could also
play a role, and there was a trend towards association be-
tween sleep apnea and antiretroviral use in these cohorts
although it did not reach significance. Sleep apnea is asso-
ciated with cardiovascular disease in the general popula-
tion [34] and may be an important mediator of increased
cardiovascular disease seen in HIV [35].
Associations between HIV status and some respiratory
outcomes differed between men and women in this study.
While this incongruity may be explained by differences
other than sex (proportions of minorities, socioeconomic
status, access to health care, and substance use), gender
differences in susceptibility to lung disease may also play a
role. Rates of asthma are greater in adult women com-
pared to men, [36] and women are more susceptible to
airflow obstruction than men given equivalent exposure to
cigarette smoking [37,38]. The influence of lung dimen-
sions and hormonal influence on airway inflammation
could explain the differences we found in which symptoms
and diagnoses were associated with HIV in women com-
pared to men.
The pathogenesis of respiratory disease in HIV-infected
persons is not completely understood and may vary by
diagnosis. Increased pulmonary and systemic inflamma-
tion may play an important role in pulmonary hyperten-
sion, [39,40] while in asthma, metabolic disease and Th2
inflammation also have significant associations [41]. Our
findings support that, in addition to traditional risk factors
for lung disease (smoking and substance abuse), factors re-
lated to HIV infection (viremia or immune suppression)
play a role in the pathogenesis in HIV-infected persons.
Antiretroviral medication has been associated with worse
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mechanism that may explain the association of antire-
troviral use and airway obstruction is immune reconstitu-
tion causing airway inflammation. Another reason for
increased respiratory disease in HIV-infected persons may
be residual lung abnormalities from prior infections or col-
onizing organisms. Recent data shows that HIV-infected
persons are still more likely to have bacterial or mycobac-
terial pneumonias [1]. Studies using culture-independent
techniques have found that detection of Pneumocystis is
associated with airflow obstruction, and this association
has been confirmed in animal studies [42-44]. In addition,
a recent study of the lung microbiome demonstrated
that HIV-infected individuals are more likely to have
Trophyrema whipplei detected in bronchoscopic alveolar
lavage, although the relationship to pulmonary function is
not known [45]. Our findings of the relationship of prior
pneumonia to respiratory complications suggest that in-
fections and resulting lung damage may be important.
Antiretroviral toxicity may also play a role. Some anti-
retroviral medications have been linked to central obesity,
which has been associated with increased inflammation
related to higher leptin and lower adiponectin levels
[46,47]. These changes may contribute to increased car-
diovascular disease in HIV, [48] and our findings suggest
obesity may play a role in certain lung diseases as well
as we found that increased body mass index is associ-
ated with several symptoms and lung diagnoses in HIV-
infected women. In the general population, obesity has
increasingly been recognized as a risk for respiratory
diseases [49].
Our study is limited in that most data were collected
from a cross-sectional assessment, and longitudinal data
on outcomes were collected over a period of only two
years. Nearly 11% and 19% of men and women, respect-
ively, in the cohorts did not complete the pulmonary
survey, with those who had completed being older and
more likely to use intravenous drugs and cocaine which
could make our prevalence and incidence estimates
higher and less generalizable to the HIV population.
Also, it may not be possible to directly invoke a specific
cardiac or respiratory cause for the symptoms reported,
but our findings suggest that both cardiac and respira-
tory disease could be potential etiologies of symptoms in
this population. Additionally, our data were obtained by
self-report which could suffer from recall or motiv-
ational bias. These limitations are counteracted by hav-
ing a large number of participants, an HIV-uninfected
group that has similar risk for HIV exposure as the HIV-
infected participants, and detailed prospective collection
of data on covariates over several decades. These cohorts
have a high prevalence of smoking and drug use which
may limit the application of our findings to other HIV
populations, although these risk factors are quite commonin HIV-infected persons in the US [10]. Differential rates
of various diagnostic testing may also lead to differential
rates of diagnosis in certain groups. Additionally, in these
cohorts, the HIV-infected groups have been followed for
several decades, with many of the originally enrolled HIV-
infected participants dying and being repopulated with
new recruits prior to our respiratory data collection. This
structure may introduce a certain amount of survival bias
and has also created a younger HIV-infected group, which
we would expect to bias away from finding differences as-
sociated with HIV.
Conclusion
In conclusion, we found that HIV infection remains an
important risk factor for respiratory diseases. These data
add to the current literature by demonstrating an in-
creased incidence of obstructive lung disease among
HIV-infected individuals and by establishing HIV as an
independent risk factor for sleep apnea. The lack of test-
ing for chronic respiratory complaints in HIV-infected
individuals suggests that the true prevalence and inci-
dence of chronic lung disease may actually be higher
than observed. Further, awareness of chronic lung dis-
eases in HIV-infected persons is necessary in order to
ensure diagnostic evaluation and appropriate treatment.
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